Next Article in Journal
Anti-Inflammatory Activity of A Polyphenolic Extract from Arabidopsis thaliana in In Vitro and In Vivo Models of Alzheimer’s Disease
Previous Article in Journal
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
Article Menu
Issue 3 (February-1) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(3), 707; https://doi.org/10.3390/ijms20030707

Podoplanin in Inflammation and Cancer

1
Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)—Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain
2
Departamento de Biotecnología-Instituto de Investigaciones Biosanitarias. Facultad de Ciencias Experimentales. Universidad Francisco de Vitoria, 28223 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Received: 30 November 2018 / Revised: 31 January 2019 / Accepted: 1 February 2019 / Published: 6 February 2019
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Full-Text   |   PDF [1279 KB, uploaded 8 February 2019]   |  

Abstract

Podoplanin is a small cell-surface mucin-like glycoprotein that plays a crucial role in the development of the alveoli, heart, and lymphatic vascular system. Emerging evidence indicates that it is also involved in the control of mammary stem-cell activity and biogenesis of platelets in the bone marrow, and exerts an important function in the immune response. Podoplanin expression is upregulated in different cell types, including fibroblasts, macrophages, T helper cells, and epithelial cells, during inflammation and cancer, where it plays important roles. Podoplanin is implicated in chronic inflammatory diseases, such as psoriasis, multiple sclerosis, and rheumatoid arthritis, promotes inflammation-driven and cancer-associated thrombosis, and stimulates cancer cell invasion and metastasis through a variety of strategies. To accomplish its biological functions, podoplanin must interact with other proteins located in the same cell or in neighbor cells. The binding of podoplanin to its ligands leads to modulation of signaling pathways that regulate proliferation, contractility, migration, epithelial–mesenchymal transition, and remodeling of the extracellular matrix. In this review, we describe the diverse roles of podoplanin in inflammation and cancer, depict the protein ligands of podoplanin identified so far, and discuss the mechanistic basis for the involvement of podoplanin in all these processes. View Full-Text
Keywords: podoplanin; C-type lectin-like receptor 2 (CLEC-2); ezrin/radixin/moesin (ERM) proteins; platelet; inflammation; thrombosis; lymphangiogenesis; epithelial–mesenchymal transition (EMT); migration; metastasis podoplanin; C-type lectin-like receptor 2 (CLEC-2); ezrin/radixin/moesin (ERM) proteins; platelet; inflammation; thrombosis; lymphangiogenesis; epithelial–mesenchymal transition (EMT); migration; metastasis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Quintanilla, M.; Montero-Montero, L.; Renart, J.; Martín-Villar, E. Podoplanin in Inflammation and Cancer. Int. J. Mol. Sci. 2019, 20, 707.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top